78 related articles for article (PubMed ID: 29341150)
1. Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer.
Koyama FC; Lopes Ramos CM; Ledesma F; Alves VAF; Fernandes JM; Vailati BB; São Julião GP; Habr-Gama A; Gama-Rodrigues J; Perez RO; Camargo AA
Br J Surg; 2018 Jan; 105(2):e192-e203. PubMed ID: 29341150
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer.
Akiyoshi T; Wang Z; Kaneyasu T; Gotoh O; Tanaka N; Amino S; Yamamoto N; Kawachi H; Mukai T; Hiyoshi Y; Nagasaki T; Yamaguchi T; Konishi T; Fukunaga Y; Noda T; Mori S
JAMA Netw Open; 2023 Jan; 6(1):e2252140. PubMed ID: 36662520
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of FCGBP expression for treatment response and survival in rectal cancer patients undergoing chemoradiotherapy.
Su YT; Chen CH; Kang JW; Kuo HY; Yang CC; Tian YF; Yeh CF; Chou CL; Chen SH
Aging (Albany NY); 2024 May; 16(9):7889-7901. PubMed ID: 38709264
[TBL] [Abstract][Full Text] [Related]
4. Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.
Wilkins A; Fontana E; Nyamundanda G; Ragulan C; Patil Y; Mansfield D; Kingston J; Errington-Mais F; Bottomley D; von Loga K; Bye H; Carter P; Tinkler-Hundal E; Noshirwani A; Downs J; Dillon M; Demaria S; Sebag-Montefiore D; Harrington K; West N; Melcher A; Sadanandam A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33678606
[TBL] [Abstract][Full Text] [Related]
5. T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Akiyoshi T; Gotoh O; Tanaka N; Kiyotani K; Yamamoto N; Ueno M; Fukunaga Y; Mori S
Cancer Immunol Immunother; 2021 Feb; 70(2):509-518. PubMed ID: 32845355
[TBL] [Abstract][Full Text] [Related]
6. Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden.
Stockton JD; Tee L; Whalley C; James J; Dilworth M; Wheat R; Nieto T; ; Geh I; Barros-Silva JD; Beggs AD
Radiat Oncol; 2021 Jul; 16(1):129. PubMed ID: 34256782
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer.
Sano S; Akiyoshi T; Yamamoto N; Hiyoshi Y; Mukai T; Yamaguchi T; Nagasaki T; Taketomi A; Fukunaga Y; Kawachi H
Clin Colorectal Cancer; 2023 Dec; 22(4):411-420.e1. PubMed ID: 37516615
[TBL] [Abstract][Full Text] [Related]
8. On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery.
Glimelius B
Ups J Med Sci; 2017 Mar; 122(1):1-10. PubMed ID: 28256956
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study.
Hodges N; Battersby N; Rao S; Brown G;
Ann Surg Oncol; 2023 Aug; 30(8):4729-4735. PubMed ID: 35771366
[TBL] [Abstract][Full Text] [Related]
10. CD11c
Tse BCY; Bergamin S; Steffen P; Hruby G; Pavlakis N; Clarke SJ; Evans J; Engel A; Kneebone A; Molloy MP
Oncoimmunology; 2023; 12(1):2238506. PubMed ID: 37485033
[TBL] [Abstract][Full Text] [Related]
11. Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol.
Mens DM; van Rees JM; Wilting SM; Verhoef C
BMC Cancer; 2023 Dec; 23(1):1187. PubMed ID: 38049783
[TBL] [Abstract][Full Text] [Related]
12. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.
Kamran SC; Lennerz JK; Margolis CA; Liu D; Reardon B; Wankowicz SA; Van Seventer EE; Tracy A; Wo JY; Carter SL; Willers H; Corcoran RB; Hong TS; Van Allen EM
Clin Cancer Res; 2019 Sep; 25(18):5561-5571. PubMed ID: 31253631
[TBL] [Abstract][Full Text] [Related]
13. MRI-based parameters and clinical risk factors to predict lymph node metastasis in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy.
Wang Y; Wang X; Huang S; Chen J; Huang Y
ANZ J Surg; 2024 Jan; ():. PubMed ID: 38251776
[TBL] [Abstract][Full Text] [Related]
14. CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.
Tian X; Nguyen M; Foote HP; Caster JM; Roche KC; Peters CG; Wu P; Jayaraman L; Garmey EG; Tepper JE; Eliasof S; Wang AZ
Cancer Res; 2017 Jan; 77(1):112-122. PubMed ID: 27784746
[TBL] [Abstract][Full Text] [Related]
15. Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.
Kalinsky K; Sparano JA; Zhong X; Andreopoulou E; Taback B; Wiechmann L; Feldman SM; Ananthakrishnan P; Ahmad A; Cremers S; Sireci AN; Cross JR; Marks DK; Mundi P; Connolly E; Crew KD; Maurer MA; Hibshoosh H; Lee S; Hershman DL
Clin Transl Oncol; 2018 Nov; 20(11):1474-1483. PubMed ID: 29736694
[TBL] [Abstract][Full Text] [Related]
16. Immune changes in hilar tumor draining lymph nodes following node sparing neoadjuvant chemoradiotherapy of localized cN0 non-small cell lung cancer.
Khalifa J; Thébault N; Scarlata CM; Norkowski E; Massabeau C; Brouchet L; Peries Bataille S; Casaroli C; Vaz L; Valle C; Sarot E; Saint-Laurent N; Martin E; Pages PB; Millière A; Mazières J; Cohen-Jonathan Moyal E; Lauzéral-Vizcaïno F; Ayyoub M
Front Oncol; 2023; 13():1269166. PubMed ID: 38074683
[TBL] [Abstract][Full Text] [Related]
17. Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.
Al-Saffar NMS; Troy H; Wong Te Fong AC; Paravati R; Jackson LE; Gowan S; Boult JKR; Robinson SP; Eccles SA; Yap TA; Leach MO; Chung YL
Br J Cancer; 2018 Oct; 119(9):1118-1128. PubMed ID: 30377337
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Tissue and Circulating miR-21 as Potential Biomarker of Response to Chemoradiotherapy in Rectal Cancer.
Ourô S; Mourato C; Ferreira MP; Albergaria D; Cardador A; Castro RE; Maio R; Rodrigues CMP
Pharmaceuticals (Basel); 2020 Sep; 13(9):. PubMed ID: 32937907
[TBL] [Abstract][Full Text] [Related]
19. A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer.
Chan J; Kinsella MT; Willis JE; Hu H; Reynolds H; Delaney C; McCulla A; Deharo S; Ahdesmäki M; Allen WL; Johnston PG; Kinsella TJ
Front Oncol; 2013; 3():288. PubMed ID: 24324931
[TBL] [Abstract][Full Text] [Related]
20. The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature.
Chauvin A; Wang CS; Geha S; Garde-Granger P; Mathieu AA; Lacasse V; Boisvert FM
Clin Proteomics; 2018; 15():16. PubMed ID: 29681787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
